RX Review: Monoclonal Antibodies for COPD Management - Episode 1
In this video, the first in a 6-part series, panelists discuss the impact of monoclonal antibodies for COPD management.
In this special report from HCPLive, Joseph Khabbaza, MD, moderates an expert discussion with Nikita Desai, MD, and Eric Costanzo, MD, on the impact of and recent developments with monoclonal antibodies in chronic obstructive pulmonary disease (COPD).
In this clip, they discuss the clinical implications of the FDA approval of mepolizumab for eosinophilic COPD and its potential to reshape treatment strategies. Costanzo and Desai highlight the significant unmet need for new therapies targeting type 2 inflammation in COPD, a disease state that has seen little innovation in decades.
Both clinicians emphasize the importance of reducing exacerbations and minimizing systemic corticosteroid exposure—2 longstanding goals that have been difficult to achieve with traditional therapies. They note that mepolizumab, supported by the phase 3 MATINEE trial, represents a paradigm shift by targeting upstream inflammatory pathways and improving outpatient disease control. The trial’s findings, including reduced exacerbation rates and the potential to delay hospital readmissions, position mepolizumab as a valuable addition to the therapeutic arsenal, particularly for patients with elevated eosinophils.
The panel also reflects on how this development mirrors the evolution of asthma care, expressing optimism that COPD treatment will follow a similar trajectory. As up to 40% of COPD patients show signs of type 2 inflammation, this biologic opens the door to more personalized and proactive management approaches that could redefine the future of COPD care.
Part 1: The Biologic Era in COPD: What Mepolizumab Approval Means for Exacerbation Control
Part 2: From Rescue to Routine: Early Use of Biologics in COPD
Part 3: Targeting Type 2 Inflammation: COPD Lessons from Asthma Biology
Part 4: Next-Gen COPD Trials: What Clinicians Need from Biologic Studies
Part 5: Identifying COPD Candidates for Biologics: What Clinicians Should Know
Part 6: EP. 6: Monoclonal Antibodies and the Future of Lung Preservation in COPD
Our Panelists:
Joseph Khabbaza, MD, is a pulmonary and critical care physician at the Cleveland Clinic and a director of the non-cystic fibrosis bronchiectasis program., who serves as the moderator for this panel discussion.
Nikita Desai, MD, is a pulmonary critical care physician at Cone Health in Greensboro, North Carolina. She is triple board certified in critical care medicine, internal medicine, and pulmonary medicine.
Eric Costanzo, MD, is a pulmonary critical care and neurocritical care physician and program director of the Pulmonary and Critical Care fellowship at Jersey Shore University Medical Center with Hackensack Meridian Health System and Shore Pulmonary Associates
Relevant disclosures for Khabbaza include Insmed, Regeneron, Sanofi, and Baxter Healthcare Corporation. Desai and Costanzo have no relevant disclosures to report.
